Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF (2020)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1161/CIRCULATIONAHA.119.044133
- Subjects: INSUFICIÊNCIA CARDÍACA; HIDROCARBONOS AROMÁTICOS; FATORES ETÁRIOS; RESULTADO DE TRATAMENTO; ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2020
- Source:
- Título do periódico: Circulation
- ISSN: 0009-7322
- Volume/Número/Paginação/Ano: v. 141, n. 2, p. 100-111, 2020
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
MARTINEZ, Felipe A et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF. Circulation, v. 141, n. 2, p. 100-111, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.044133. Acesso em: 17 abr. 2024. -
APA
Martinez, F. A., Serenelli, M., Nicolau, J. C., Petrie, M. C., Chiang, C. -E., Tereshchenko, S., et al. (2020). Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF. Circulation, 141( 2), 100-111. doi:10.1161/CIRCULATIONAHA.119.044133 -
NLM
Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF [Internet]. Circulation. 2020 ; 141( 2): 100-111.[citado 2024 abr. 17 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044133 -
Vancouver
Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF [Internet]. Circulation. 2020 ; 141( 2): 100-111.[citado 2024 abr. 17 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044133 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
- Anticoagulação e antiagregação plaquetária nas síndromes isquêmicas miocárdicas instáveis [Carta]
Informações sobre o DOI: 10.1161/CIRCULATIONAHA.119.044133 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
